The Thromboelastography: Clinical Significance of Functional Fibrinogen Test

A.Yu. Bulanov1, 2, K.V. Yatsckov1, E.L. Bulanova1,3, N.V. Dobrova1

1 52th Moscow City hospital, Moscow

2 Russian University of Friendship, Moscow

3 First Moscow Medical University, Moscow

For correspondence: Bulanov Andrey Yulievich — Doctor of Medical Science, Head of consultative transfusiology team of 52th Moscow City hospital, Professor of Department of Anesthesiology and Reanimatology of Russian University of Friendship, Moscow; e-mail: buldoc68@mail.ru

For citation: Bulanov AYu, Yatsckov KV, Bulanova EL, Dobrova NV. The Thromboelastography: Clinical Significance of Functional Fibrinogen Test. Intensive Care Herald. 2017;1:5–11.


The hemostatic system is a frequent subject of interest of critical care. Critical hemostasis has been studied most commonly using thromboelastography. Presented study report the experience in the use of special TEG technology fictional fibrinogen test. As the main working area of FF-test should be marked posthemorrhagic coagulopathy, a situation demanding close attention to the function of the platelets when combined with hyperfibrinogenemia (increase in fibrinogen associated with nonspecific inflammation, gestational hyperofibrinogenemia). A significant difference (more than 2 g/l) between the level of fibrinogen of the plasma is estimated by the method of Claus and FF-test can serve as a marker of dysfibrinogenemia. The clinical importance of the methodology is a predictor of thrombotic and haemorrhagic problems, the diagnostic marker, a reference point for the purpose of transfusion therapy.

Keywords: thromboelastography, functional fibrinogen, bleeding, thrombosis, intensive care

Received: 21.01.2017 


References

  1. Harr J.N., Moore E.E., Chasabyan A. et al. Functional fibrinogen assay indicates that fibrinogen is critical in correcting abnormal clot strength following trauma. Shock. 2013; 39(1): 45–19. doi: 10.1097/SHK.0b013e3182787122.
  2. Parker R.J., Eley K.A., Von Kier S. et al. Functional fibrinogen to platelet ratio using thromboelastography as a predictive parameter for thrombotic complications following free tissue transfer surgery: a preliminary study. 2012; 32(7): 512–519. doi: 10.1002/micr.21978.
  3. Буланов А.Ю. Тромбоэластография в современной клинической практике. Атлас ТЭГ. М.: Ньюдиамед, 2015. [Bulanov A.Yu. Tromboelastografiya v sovremennoi klinicheskoi praktike. Atlas TEG. Moscow: N’udiamed, 2015. (In Russ)]
  4. Chen A., Teruya J. Global hemostasis testing thromboelastography: old technology, new applications. Clin. Lab. Med. 2009; 29: 391–407. doi: 10.1016/j.cll.2009.04.003.
  5. Solomon C., Ranucci M., Hochleitner G. et al. Assessing the methodology for calculating platelet contribution to clot strength in thromboelastometry and thromboelastography. Analg. 2015; 121: 868–878. doi: 10.1213/ANE.0000000000000859.
  6. Carroll R.C., Craft R.M., Chavez J.J. et al. Measurement of functional fibrinogen levels using the thrombelatograph. Clin. Anesth. 2008; 20(3): 186–190. doi: 10.1016/j.jclinane.2007.09.017.
  7. Pruller F., Raggan R.B., Mahla E. et al. Whole blood fibrinogen test results in thromboelastography and thromboelastometry — which one is true? Transfusion Med.. 2014: 24(suppl. 1): 45.
  8. De Pietry L., Raqusa F., Deleuterio A. et al. Reduce transfusion during OLT by POC coagulation management and TEG fictional fibrinogen. Transplant Direct. 2015; 2(1): 49. doi: 10.1097/TXD.0000000000000559.
  9. Fluger I., Maderova K., Simek M. et al. Comparison of functional fibrinogen assessment using thromboelastography with the standard von Clauss method. Biomed. Pap. Med. Fac. Univ. Olomouc. Czech. Repub. 2012; 156: 260–261. doi: 10.5507/bp.2011.035.

Experience with the use of antithrombin III concentrate in a multidisciplinary clinic

I.S. Kiriienko1, A.Yu. Bulanov1, 2, I.B. Simarova2, S.V. Dzuba2

1 Peoples’ Friendship University of Russia, Moscow

2 City Clinical Hospital № 52, Moscow

For correspondence: Kiriienko Iryna Sergeevna — resident of the anesthesiology and intensive care department, medical institute, RUDN, Moscow

For citation: Kiriienko IS, Bulanov AYu, Simarova IB, Dzyuba SV. Experience with the use of Antithrombin III concentrate in a multidisciplinary clinic. Alexander Saltanov Intensive Care Herald. 2018;2:46–50.

DOI: 10.21320/1818-474X-2018-2-46-50


Thrombosis and thromboembolism are one of the frequent serious and complications in all groups of patients and can lead to death. The purpose of our study was to analyze the clinical situations that required the use of antithrombin concentrate in the practice of intensive care units within the framework of a multidisciplinary hospital. A retrospective analysis was performed of the treatment of 38 patients with acquired antithrombin deficiency in 2016, which was treated with antithrombin. The analysis of the clinical situations that required the use of antithrombin concentrate revealed that the most frequent need for the use of the drug occurs in patients with malignant blood diseases, liver and kidney diseases and in patients with sepsis. Also, the calculation methods for determining the required dosage do not provide an optimal level of AT activity, and the efficacy of anticoagulant therapy does not depend on the total dosage of the drug administered.

Keywords: antithrombin, anticoagulant therapy, thrombosis, thromboembolism

Received: 12.03.2018


References

  1. Клигуненко Е.Н. Система гемостаза и венозный тромбоз: последствия, профилактика, лечение. Медицина неотложных состояний. 2008; 3: 16. [Kligunenko E.N.Sistema gemostaza i venoznyiy tromboz (posledstviya, profilaktika, lechenie). Meditsina neotlozhnyih sostoyaniy. 2008; 1: 16. (In Russ)]
  2. ПолоховД.М., Баландина А.Н., Сошитова Н.П. и др. Лабораторный контроль гепаринотерапии у больных с высоким риском венозных тромбозов. Материалы 45-го Всероссийского образовательного форума «Теория и практика анестезии и интенсивной терапии в акушерстве и гинекологии». Москва — Балашиха. 4–5 февраля 2016 года. [Polohov D.M., Balandina A.N., Soshitova N.P., et al. Laborotornyiy kontrol geparinoterapii u bolnyih s vyisokim riskom venoznyih trombozov. Materialyi 45 Vserossiyskogo obrazovatelnogo foruma «Teoriya i praktika anestezii i intensivnoy terapii v akusherstve i ginekologii». Moskva — Balashiha. 4–5 fevralya 2016 goda. (In Russ)]
  3. Jones A.J., OʼMara K.L., Kelly B.J., Samraj R.S. The Impact of Antithrombin III Use in Achieving Anticoagulant Goals in Pediatric Patients. J. Pediatr. Pharmacol. Ther. 2017; 22(5): 320–325.
  4. ЗалюбовскаяО.И., Литвинова О.Н., Киреев И.В. и др. Клиническая лабораторная диагностика: Курс лекций. Харьков: Издательство НФаУ, 2008. [Zalyubovskaya O.I., Litvinova O.N., Kireev I.V., et al. Klinicheskaya laboratornaya diagnostika: Kurs lektsiy. Kharkov: Izdatelstvo NFaU, 2008. (In Russ)]
  5. Kristina M.Nelson, Lizbeth A. Hansen, Marie E. Steiner, et al. Continuous Antithrombin III Administration in Pediatric Veno-Arterial Extracorporeal Membrane Oxygenation. J. Pediatr. Pharmacol. Ther. 2017; 22(4): 266–271.
  6. Dunzendorfer S., Kaneider N., Rabensteiner A., et al. Cell‐surface heparan sulfate proteoglycan‐mediated regulation of human neutrophil migration by the serpin antithrombin III. Blood. 2001; 97: 1079–1085.
  7. Kellner P., Nestler F., Leimert A., et al. Antithrombin III, but not C1 esterase inhibitor reduces inflammatory response in lipopolysaccharide‐stimulated human monocytes in an ex‐vivo whole blood setting. Cytokine. 2014; 70: 173–178.
  8. Lane D.A., Olds R.J., Conard J., et al. Pleiotropic effects of antithrombin strand 1C substitution mutations. J. Clin. Invest. 1992; 90: 2422–2433.
  9. Águila S., Navarro-Fernández J., Bohdan N., et al. Role of the C-sheet in the maturation of N-glycans on antithrombin: functional relevance of pleiotropic mutations. J. Thromb. Haemost. 2014; 12: 1131–1140.
  10. Martínez-Martínez I., Navarro-Fernández J., Ostergaard A., et al. Amelioration of the severity of heparin-binding antithrombin mutations by posttranslational mosaicism. Blood. 2012; 120: 900–904.
  11. Koide T., Odani S., Takahashi K., et al. (1984) Antithrombin III Toyama: replacement of arginine-47 by cysteine in hereditary abnormal antithrombin III that lacks heparin-binding ability. Proc. Natl. Acad. Sci. U.S.A. 1984; 81: 289–293.
  12. Raja S.M., Chhablani N., Swanson R., et al. Deletion of P1 arginine in a novel antithrombin variant (antithrombin London) abolishes inhibitory activity but enhances heparin affinity and is associated with early onset thrombosis. J. Biol. Chem. 2003; 278: 13688–13695.
  13. Ribeiro A.A., Lourenco D.M., Toledo C.F., et al. Antithrombin III concentrate use in patients with cirrhosis with coagulation disorders. Rev. Assoc. Med. Bras. 1997; 43: 189–194.
  14. Bushman J.E., Palmeri D., Whinna H.C., Church F.C. Insight into the mechanism of asparaginase-induced depletion of antithrombin III in treatment of childhood acute lymphoblastic leukemia. Leuk.Res. 2000; 24: 559–565.
  15. ЛопатинА.Ф. Теория и практика анестезии и интенсивной терапии в акушерстве и гинекологии. Материалы 45-го Всероссийского образовательного форума. Москва — Балашиха. 4–5 февраля, 2016. [Lopatin A.F. Teoriya i praktika anestezii i intensivnoy terapii v akusherstve i ginekologii. Materialyi 45 Vserossiyskogo obrazovatelnogo foruma. Moskva — Balashiha. 4–5 fevralya, 2016. (In Russ)]
  16. Справочник Видаль. Лекарственные препараты вРоссии. Официальная инструкция по применению «Антитромбин III человеческий».Vidalgroup, 2014. [Spravochnik Vidal. Lekarstvennyie preparatyi v Rossii. Ofitsialnaya instruktsiya po primeneniyu “Antitrombin III chelovecheskiy”.Vidalgroup, 2014. (In Russ)]